EADV 2026 at a glance
At 2026,will differentiation in dermatology move beyond mechanism and initial efficacy toward treatment durability, reduced treatment burden and improved outcomes in harder-to-treat disease? From atopic dermatitis and hidradenitis suppurativa to alopecia areata and psoriasis, the congress is set to highlight emerging opportunities for clinical and competitive differentiation.
📅 Build your schedule around the topics that matter most.
📥 Download the EADV 2026_Preview_by_LucidQuest
Key Dermatology Treatment Trends to Watch at EADV 2026
Atopic Dermatitis: IL-13, IL-18, JAK Inhibitors and Emerging Therapies
IL-13, IL-18, IL-4Rα, JAK and regulatory T-cell approaches will compete on durability, difficult-to-treat sites, dosing and treatment simplicity.
Hidradenitis Suppurativa: Tulisokibart, Lutikizumab and Abdakibart
Tulisokibart, lutikizumab and abdakibart will test whether targeting inflammatory and fibrotic biology translates into meaningful differentiation in tunnels, scarring and deeper disease.
Alopecia Areata: Bempikibart, Ritlecitinib and Baricitinib
Bempikibart, ritlecitinib and baricitinib data will shift attention toward long-term disease control, treatment-free response and adolescent treatment.
Psoriasis: Icotrokinra, Zasocitinib and Oral Treatment Competition
Two-year icotrokinra data and zasocitinib versus deucravacitinib could raise expectations for oral psoriasis therapies beyond convenience alone.
Competitor and Industry Signals at EADV 2026
Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly and UCB: Dermatology Competition
Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly, UCB and other companies are emphasizing earlier intervention, sustained disease control and more individualized systemic treatment strategies.
Emerging Dermatology Pipeline: New Mechanisms and Clinical Data
Oturkibart, zumilokibart/APG777, bempikibart, daxdilimab, lunsekimig, tulisokibart and MG-K10 add new mechanisms and late-breaking datasets to watch.
Artificial Intelligence and Machine Learning at EADV 2026
AI in Dermatology: Diagnosis, Melanoma Risk Prediction and Dermoscopy
Sessions will focus on AI-supported diagnosis, melanoma risk prediction, dermoscopy, teledermatology and image-based assessment rather than drug discovery.
Clinical Integration: MELAPRED, Vision Transformers and 3D Imaging
MELAPRED, Vision Transformer dermoscopy and 3D total-body photography will test whether AI can add value alongside dermatologist assessment.
What We Are Watching After EADV 2026
- Whether emerging hidradenitis suppurativa mechanisms translate into clinically meaningful differentiation.
- Whether oral psoriasis therapies deliver deeper, durable disease control at high-impact sites.
- Whether longer-term clinical datasets establish treatment durability as a stronger competitive differentiator.
- Whether AI evidence is strong enough to support routine dermatology diagnosis, risk assessment and monitoring.
Download the EADV 2026 Preview Report
Download LucidQuest’s EADV 2026 preview report for deeper analysis of emerging dermatology treatments, clinical developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the EADV 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
